Zimbabwe has declined a major US health deal valued at $367m (£272m) spanning five years over Washington's request for sensitive data.
The decision became public after a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesman has since clarified that the United States was seeking health data for scientific study and commercial purposes but was not willing to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more negotiations to secure a agreement agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Background
Zimbabwe's decision follows a comparable case in Kenya, where a court suspended a related health funding agreement after concerns were filed about the security of citizens' health data.
After resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
Based on statements, Sixteen nations in Africa have to date signed these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information over an extended period, without any equivalent promise of benefiting from any medical innovations – like new medicines or tests – that could be developed from that shared data," he stated.
"Put simply, our country would provide the raw materials for scientific discovery without any assurance that the final treatments would be accessible to our citizens if a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were upending structures already established through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a country contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration could be designed in a way that honours the sovereignty and interests of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the official position, but recommended that talks must proceed since much of the nation's HIV programmes relied on foreign aid.
"Where specific concerns arise, such as those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it said.
The halted deal underscores the continuing tensions between receiving crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.